Compass Pathways set for worst-day ever after depression drug data disappoints Wall Street

COMPASS Pathways

23/06/2025 15:06

Updates

** Shares of drug developer Compass Pathways CMPS.O fall 44.7% to $2.57

** Stock set for biggest one-day percentage fall ever, if losses hold

** Co says its experimental psilocybin-based therapy helped significantly reduce the symptoms of difficult-to-treat depression in a late-stage study

** This was measured on a standardized depression scale after six weeks of treatment where the drug reduced depression by 3.6 points compared to a placebo

** However, investors were expecting a five point difference, brokerage RBC Capital Markets said in May

** Including session's move, CMPS stock down 28.5% YTD

 (Reporting by Puyaan Singh and Padmanabhan Ananthan)

 ((Puyaan.Singh@thomsonreuters.com;))